$10 Billion Deal, page-1183

Extract from Half Yearly Report.


For the second half of the financial year, the Company will be focused on the following activities:
• Completion of detailed analyses from the Phase 2 HIV-1 clinical trial, locking of the trial database, unblinding and statistical analyses of the data, and release of results. • Continued testing of Biotron compounds for activity against other key commercially relevant virus targets. • Aiming to execute partnership agreement(s) for the Company’s antiviral programs in worldwide markets.